2-(2-morpholin-4-yl-2-oxo-ethyl)-5-phenyl-pentanoic Acid → 2-(2-Morpholin-4-yl-2-oxo-ethyl)-5-phenyl-pentanoic acid, (S)-1-(5-phenyl-[1,2,4]oxadiazole-3-carbonyl)-propyl-amide

Participants

Reaction Steps

Similarly prepared according to the procedure for Example 43 but using 2-(2-morpholin-4-yl-2-oxo-ethyl)-5-phenyl-pentanoic acid and (S)-2-amino-1-(5-phenyl-[1,2,4]oxadiazol-3-yl)-butan-1-ol; MS: 541 (M+Na), LCMS retention time 4.44 and 4.53 min; 1H NMR (CDCl3) 8.18 (d, J=7 Hz, 2H), 7.69–7.51 (m, 3H), 7.27–7.10 (m, 5H), 6.99–6.7 (d, J=7 Hz, 1H), 5.38 (m, 1H), 3.70–3.36 (m, 8H), 2.99–2.56 (m, 4H), 2.27 (m, 1H), 2.11 (m, 1H), 1.87–1.60 (m, 4H), 1.44 (m, 1H), 1.02–0.97 (dt, J=7 Hz, 3H).

Provenance & Evidence